Abstract
We investigated the prognostic value of pituitary tumor transforming gene 1 (PTTG1) expression according to clinicopathological features among localized or locally advanced prostate cancer cases receiving hormone therapy. A retrospective study involved 64 patients receiving combined androgen blockade treatment was performed. PTTG1 expression was determined by immunohistochemical staining using initial needle biopsy specimens for diagnosis. Associations of PTTG1 with various clinicopathological features and disease-free survival were examined via uni- and multivariate analyses. No association between PTTG1 expression and clinical T stage, Gleason score, pretreatment PSA levels, risk groups was found (p=0.682, 0.184, 0.487, 0.571, respectively). Univariate analysis revealed that increased PTTG1 expression, T3 stage and high risk group were associated with increased risk of disease progression (p=0.000, 0.042, and 0.001), and high PSA level had a tendency to predict disease progression (p=0.056). Cox hazard ratio analysis showed that PTTG1 low expression (p=0.002), PTTG1 high expression (p=0.000) and high risk group (p=0.0147) were significantly related to decreased disease-free survival. In conclusion, PTTG1 expression determined by immunohistochemical staining in needle biopsy specimens for diagnosis is a negative prognostic factor for progression in localized or locally advanced prostate cancer receiving hormone therapy.
Highlights
Prostate cancer represents a major global public health issue, and are the most frequently diagnosed tumor and the second largest cancer contributing to mortality in men in USA
We investigated the prognostic value of pituitary tumor transforming gene 1 (PTTG1) expression according to clinicopathological features among localized or locally advanced prostate cancer cases receiving hormone therapy
HR, Hazard Ratio; CI, confidence interval; Cox proportional hazard model and single parameter analysis was used to determine the prognostic significance of age group, Gleason score (GS) group, T stage (T3/T2), pretreatment PSA level, risk group and PTTG1 expression; All were used as categorical variables was 53.4 months, negative expression 94.0 months
Summary
Prostate cancer represents a major global public health issue, and are the most frequently diagnosed tumor and the second largest cancer contributing to mortality in men in USA. PTTG1 expression determined by immunohistochemical staining in needle biopsy specimens for diagnosis is a negative prognostic factor for progression in localized or locally advanced prostate cancer receiving hormone therapy.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
